Section 9.2: Diabetic Foot Infection & Osteomyelitis Management

Diabetic Foot Infection & Osteomyelitis Management

Diabetic foot infections (DFIs) represent a major clinical emergency in wound care. Hyperglycemia-induced immune dysfunction—characterized by impaired leukocyte chemotaxis, defective phagocytosis, and blunted intracellular bactericidal killing—renders diabetic patients highly susceptible to rapidly progressive soft tissue destruction and bone infection. Over 20% of mild DFIs and up to 60% of severe DFIs progress to Diabetic Foot Osteomyelitis (DFOM). Accurate classification of infection severity, prompt bedside diagnostics, timely imaging, and aggressive multidisciplinary surgical and antimicrobial management are vital to prevent limb amputation.

---

IDSA / IWGDF Infection Severity Classification

The Infectious Diseases Society of America (IDSA) and the International Working Group on the Diabetic Foot (IWGDF) established a standardized four-tier clinical grading system for DFIs. This framework categorizes infections based on local tissue involvement, anatomical depth, erythema demarcation, and systemic inflammatory manifestations.

┌────────────────────────────────────────────────────────────────────────┐
│                 IDSA / IWGDF INFECTION SEVERITY TRIAGE                 │
└───────────────────────────────────┬────────────────────────────────────┘
                                    │
        ┌───────────────────────────┴───────────────────────────┐
        ▼                                                       ▼
┌──────────────┐                                        ┌──────────────┐
│  LOCALIZED   │                                        │   SYSTEMIC   │
│ (No SIRS)    │                                        │  SIRS (≥2)   │
└───────┬──────┘                                        └──────┬───────┘
        │                                                      │
  ┌─────┴─────────────────────┐                                ▼
  ▼                           ▼                         ┌──────────────┐
┌──────────────┐       ┌──────────────┐                 │   GRADE 4    │
│   GRADE 2    │       │   GRADE 3    │                 │   SEVERE     │
│ Mild (≤2 cm, │       │Moderate(>2cm │                 │ Inpatient IV │
│ Superficial) │       │ or Deep)     │                 │ Surgical De- │
│ Oral Abx     │       │ Oral/IV Abx  │                 │ compression  │
└──────────────┘       └──────────────┘                 └──────────────┘

---

Microbiology of Diabetic Foot Infections

The microbial etiology of DFIs varies significantly based on infection depth, duration, and prior antibiotic exposure:

• Mild, Acute, Superficial DFIs in Antibiotic-Naïve Patients: Typically monomicrobial, dominated by Gram-positive aerobic cocci, predominantly Staphylococcus aureus (including methicillin-resistant S. aureus [MRSA]) and Streptococcus agalactiae (Group B Strep) or Streptococcus pyogenes.
• Moderate to Severe, Chronic, Deep DFIs: Predominantly polymicrobial (average 3–5 species per wound). Pathogens include Gram-positive cocci, Gram-negative bacilli (Enterobacteriaceae such as Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and non-fermenters like Pseudomonas aeruginosa), and obligate anaerobes (Bacteroides fragilis, Peptostreptococcus spp., Clostridium spp.). Anaerobes thrive in necrotic, ischemic, deep plantar space infections.

---

Bedside Diagnostic Testing: Probe-to-Bone (PTB) Test

The Probe-to-Bone (PTB) test is a simple, highly effective bedside clinical examination maneuver performed to evaluate underlying osteomyelitis in an open diabetic foot wound.

   Sterile Metal Probe
      ───────┐
             │   ┌───────────────────────────┐
             └──►│  Deep Plantar Foot Ulcer  │
                 └─────────────┬─────────────┘
                               │
                               ▼
            ┌────────────────────────────────────┐
            │ Palpable Hard, Rigid, Gritty Bone? │
            └──────────────────┬─────────────────┘
                               │
                 ┌─────────────┴─────────────┐
                 ▼                           ▼
        ┌─────────────────┐         ┌─────────────────┐
        │  POSITIVE PTB   │         │  NEGATIVE PTB   │
        │ High PPV (>85%) │         │ High NPV in Low │
        │ Workup DFOM     │         │ Risk Outpatients│
        └─────────────────┘         └─────────────────┘

Clinical Technique

After gentle wound cleansing, a sterile, blunt-tipped metallic probe (e.g., stainless steel probe) is inserted through the ulcer base without applying excessive force. The clinician systematically probes the ulcer floor, assessing for contact with a hard, solid, gritty structure.

Interpretation & Diagnostic Utility

• Positive PTB Test: Defined as palpating a hard, rigid, unyielding, or gritty bone surface with the metal probe.
• Diagnostic Performance:
  • In high-prevalence populations (hospitalized patients, deep ulcers, chronic non-healing ulcers over bony prominences), a positive PTB test has a Positive Predictive Value (PPV) of 85% to 90% for diabetic foot osteomyelitis.
  • In low-prevalence populations (outpatient clinic, superficial non-infected ulcers), a negative PTB test has a high Negative Predictive Value (NPV), helping rule out bone involvement.

---

Diagnostic Imaging Modalities for Osteomyelitis

Accurate diagnosis of diabetic foot osteomyelitis (DFOM) requires integrating clinical assessment with diagnostic imaging modalities.

Differentiating Osteomyelitis from Charcot Neuroarthropathy

Differentiating active osteomyelitis from acute Charcot Neuroarthropathy (Charcot foot) is a classic CWS exam challenge:

• Osteomyelitis: Typically focal, localized directly beneath an open ulcer or sinus tract; bone marrow edema is unifocal.
• Charcot Neuroarthropathy: Typically joint-centered, polyarticular, involving tarsometatarsal (Lisfranc) or midtarsal joints; occurs in intact skin or distant from ulcers; bone marrow edema is periarticular and multi-osseous.

Bone Biopsy: The Diagnostic Gold Standard

While MRI is the gold standard non-invasive imaging modality, bone biopsy (obtained percutaneously through uninfected skin or intraoperatively during debridement) remains the definitive gold standard for confirming osteomyelitis.

• Histopathology: Demonstrates osteonecrosis, marrow trabecular erosion, and dense inflammatory infiltrates (neutrophils in acute OM; lymphocytes, plasma cells, and histiocytes in chronic OM).
• Microbiology: Culturing aseptic bone tissue isolates the true pathogen(s), guiding targeted antimicrobial therapy and avoiding narrow treatment of superficial wound colonizers.

---

Therapeutic Management of Osteomyelitis

Management of DFOM requires a balanced approach combining antimicrobial therapy, surgical intervention, mechanical off-loading, and glycemic control.

1. Antimicrobial Therapy Strategy

• Empiric Therapy: Initial broad-spectrum coverage based on IDSA severity. For Grade 3/4 infections, IV regimens include vancomycin or daptomycin (for MRSA) plus piperacillin-tazobactam, cefepime, or meropenem (for Gram-negative bacilli and anaerobes).
• Definitive Targeted Therapy: Tailored to bone biopsy cultures.
• Duration of Therapy:
  • Post-Surgical Complete Resection (Clean Bone Margins): 2 to 5 days of parenteral/oral antibiotics (short course).
  • Resection with Residual Soft Tissue Infection: 1 to 2 weeks of targeted antibiotics.
  • Viable Infected Bone Remaining (Conservative Medical Management / Partial Resection): 4 to 6 weeks of parenteral or high-bioavailability oral antibiotics (e.g., fluoroquinolones, linezolid, trimethoprim-sulfamethoxazole, clindamycin, combined with rifampin for biofilm eradication).
  • No Surgical Resection (Strict Medical Management): 6 to 12 weeks of antimicrobial therapy.

2. Surgical Management Indications

Emergency surgical intervention is indicated for:

1. Grade 4 Severe DFIs with systemic sepsis.
2. Deep plantar space abscesses, necrotizing fasciitis, or gas gangrene.
3. Progressive soft tissue necrosis or gangrene (Wagner Grade 4/5).
4. Refractory osteomyelitis with cortical sequestration or unviable bone destruction.